DOCSLIB.ORG

NZMJ 1517.Indd

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
NZMJ 1517.Indd Journal of the New Zealand Medical Association Vol 133 | No 1517 | 26 June 2020 Mass masking: an alternative to a second lockdown in Aotearoa Asthma and Respiratory Foundation NZ Adolescent and Adult Asthma Guidelines 2020: a quick reference guide Medical considerations for supporting elite athletes during the post-peak phase of the New Zealand COVID-19 pandemic: a New Zealand sporting code consensus Te Hā o Whānau: A culturally E-cigarettes, vaping and Is snacking the new eating responsive framework of a Smokefree Aotearoa: norm for New Zealand children? maternity care where to next? An urgent call for research Publication Information published by the New Zealand Medical Association NZMJ Editor NZMA Chair Professor Frank Frizelle Dr Kate Baddock NZMJ Production Editor NZMA Communications Manager Rory Stewart Diana Wolken Other enquiries to: NZMA To contribute to the NZMJ, fi rst read: PO Box 156 www.nzma.org.nz/journal/contribute The Terrace Wellington 6140 © NZMA 2020 Phone: (04) 472 4741 To subscribe to the NZMJ, email [email protected] Subscription to the New Zealand Medical Journal is free and automatic to NZMA members. Private subscription is available to institutions, to people who are not medical practitioners, and to medical practitioners who live outside New Zealand. Subscription rates are below. All access to the NZMJ is by login and password, but IP access is available to some subscribers. Read our Conditions of access for subscribers for further information www.nzma.org.nz/journal/subscribe/conditions-of-access If you are a member or a subscriber and have not yet received your login and password, or wish to receive email alerts, please email: [email protected] The NZMA also publishes the NZMJ Digest. This online magazine is sent out to members and subscribers six times a year and contains selected material from the NZMJ, along with all obituaries, summaries of all articles, and other NZMA and health sector news and information. Subscription rates for 2020 New Zealand subscription rates Overseas subscription rates Individuals* $349 Individual $486 Institutions $604 Institutions $650 Individual article $33 Individual article $33 *NZ individual subscribers must not be doctors (access is via NZMA Membership) New Zealand rates include GST. No GST is included in international rates. Note, subscription for part of a year is available at pro rata rates. Please email [email protected] for more information. Individual articles are available for purchase by emailing [email protected] NZMJ 26 June 2020, Vol 133 No 1517 ISSN 1175-8716 © NZMA 2 www.nzma.org.nz/journal CONTENTS EDITORIALS 66 8 Te Hā o Whānau: A culturally Mass masking: an alternative to a responsive framework of second lockdown in Aotearoa maternity care Amanda Kvalsvig, Nick Wilson, Kendall Stevenson, Sara Filoche, Ling Chan, Sophie Febery, Sally Roberts, Fiona Cram, Beverley Lawton Bryan Betty, Michael G Baker GUIDELINES 14 E-cigarettes, vaping and a 73 Asthma and Respiratory Smokefree Aotearoa: where Foundation NZ Adolescent and to next? Adult Asthma Guidelines 2020: a Richard Edwards, Janet Hoek, Andrew Waa quick reference guide Richard Beasley, Lutz Beckert, ARTICLES James Fingleton, Robert J Hancox, Matire Harwood, Miriam Hurst, 18 Stuart Jones, Susan Jones, Ciléin Social consequences of assisted Kearns, David McNamara, Betty Poot, dying: a case study Jim Reid Rhona Winnington, Roderick MacLeod VIEWPOINTS 24 Demographics of New Zealand 100 women with vulval lichen Human lungs are created to sclerosus: is specialist care breathe clean air: the questionable equitable? quanti cation of vaping safety Harriet S Cheng, Coco Kerckho s, “95% less harmful” Nicky Perkins, Lois Eva Kelly S Burrowes, Lutz Beckert, Stuart Jones 32 Performance of CVD risk 107 equations for older patients Medical considerations for assessed in general practice: a supporting elite athletes during cohort study the post-peak phase of the Sue Wells, Romana Pylypchuk, New Zealand COVID-19 pandemic: Suneela Mehta, Andrew Kerr, a New Zealand sporting code Vanessa Selak, Katrina Poppe, consensus Corina Grey, Rod Jackson Bruce Hamilton, Lynley Anderson, Nat Anglem, Stuart Armstrong, 56 Simon Baker, Sarah Beable, Surveillance for dysplasia in Peter Burt, Lynne Coleman, patients with in ammatory bowel Rob Doughty, Tony Edwards, Dan Exeter, disease: an updated national Mark Fulcher, Stephen Kara, survey of colonoscopic practice in John Mayhew, Sam Mayhew, Chris New Zealand Milne, Tamara Glyn Mullaney, Brendan O’Neill, Hamish Osborne, Andrew McCombie, Melinda Parnell, Jake Pearson, Christopher Wakeman, Karen Rasmussen, Judikje Sche er, Timothy Eglinton, Richard Gearry Martin Swan, Mark Thomas, David Gerrard NZMJ 26 June 2020, Vol 133 No 1517 ISSN 1175-8716 © NZMA 3 www.nzma.org.nz/journal CONTENTS CLINICAL CORRESPONDENCE 131 117 Is snacking the new eating norm for Ocular complications from primary New Zealand children? An urgent varicella infection call for research Aaron Yap, Joanne L Sims, Christy O’Toole, Ryan Gage, Rachael L Niederer Christina McKerchar, Viliami Puloka, Rachael McLean, Louise Signal 123 Simultaneous ischaemic and 133 haemorrhagic strokes in a Can we teach psychiatry in medical hypertensive man: a manifestation school in a better way? of cerebral small vessel disease Nicholas R Wilson Karim M Mahawish, Almond Leung 100 YEARS AGO 126 135 An unexpected case of Gonorrhoea: Some Notes on disseminated tuberculosis from the Evil Results of its Abortive tumour necrosis factor inhibition Treatment in the A.I.F. Danny Con, Andrew Gador-Whyte, By FRANK MACKY, M.B., B.S. (Melb.). Robert MacGinley LETTERS 129 Health advice for counselling: would parvovirus infection in puppies affect children and women? Kam Lun Hon, Karen Ka Yan Leung NZMJ 26 June 2020, Vol 133 No 1517 ISSN 1175-8716 © NZMA 4 www.nzma.org.nz/journal SUMMARIES Social consequences of assisted dying: a case study Rhona Winnington, Roderick MacLeod This paper discusses the potential effects of assisted dying (AD) legislation beyond the relief of individual suffering. AD is when an individual chooses that they wish to die and either self-medicate to end their life under clinical supervision, or clinicians administer the medi- cation for them. This paper focuses on potential family/whānau and community consequences should we introduce such legislation into New Zealand culture, highlighting that family members whose loved one has had an assisted death are feeling obligated to also consider dying in this way as their health fails. Furthermore, we highlight that even when AD is a legal option, all those involved in the assisted death remain secretive about what has occurred due to a fear of being judged by others. Finally, we offer insight into a concerning potential side- effect of AD legislation; that is that when individuals are exposed to someone considering an assisted death, they too will also consider using this legislation. This participant describes the effect of AD legislation as being infectious. Demographics of New Zealand women with vulval lichen sclerosus: is specialist care equitable? Harriet S Cheng, Coco Kerckho s, Nicky Perkins, Lois Eva Vulval lichen sclerosus is an autoimmune skin condition which can cause infl ammation, scarring and increased risk of cancer in genital skin. Around 1% of women are affected. This study examined cases of lichen sclerosus seen by dermatology, gynaecology and sexual health at Auckland District Health Board. We found most women seen were of New Zealand European ethnicity and compared with Census data for our region, European women were over-represented. Māori, Pacifi c and Asian women were under-represented. Causes for this inequitable ethnic representation may include sociocultural beliefs, variations in access to care or ethnic differences in the prevalence of lichen sclerosus. Further study is required to deepen our understanding and allow work to reduce inequity. Performance of CVD risk equations for older patients assessed in general practice: a cohort study Sue Wells, Romana Pylypchuk, Suneela Mehta, Andrew Kerr, Vanessa Selak, Katrina Poppe, Corina Grey, Rod Jackson Cardiovascular disease (CVD) is the leading cause of preventable health loss for older people, many of whom are still engaged in the workforce and physically active. The current Ministry of Health CVD guidelines recommend that GPs consider doing a routine heart check using New Zealand CVD risk equations for healthy people over 75 years and discuss the same management options as for people under 75 years of age. However, risk assessment and management is more complex for older age groups as health status varies greatly. The risk of other long-term conditions increases with age and this in turn is associated with complicated medication regimens. As a fi rst step, we investigated how well current CVD risk equations (developed for people 30–74 years) performed for over 40,000 older people for whom GPs considered suitable for routine preventive CVD risk assessment. We found current CVD risk equations underestimated fi ve-year CVD hospitalisations or deaths for women from 75 years and men from 80 years. NZMJ 26 June 2020, Vol 133 No 1517 ISSN 1175-8716 © NZMA 5 www.nzma.org.nz/journal SUMMARIES Surveillance for dysplasia in patients with in ammatory bowel disease: an updated national survey of colonoscopic practice in New Zealand Tamara Glyn Mullaney, Andrew McCombie, Christopher Wakeman, Timothy Eglinton, Richard Gearry Infl ammatory bowel disease patients are at a higher risk of developing colorectal cancer and so undergo surveillance endoscopy to identify the changes (dysplasia) at an early stage. In the past, it has been diffi cult to see all these changes (and sometimes even cancers), so we have tended to treat these patients (even with early changes) by removing their large bowel. Current techniques are more accurate at identifying the changes and this survey suggests New Zealand endoscopists are using them appropriately, however we are possibly still recom- mending removal of the large bowel more often than is necessary. Perhaps some of these patients will be able to be managed with the advanced techniques safely and avoid the need to their remove their bowel at this stage.
Load more

Recommended publications
  • IQI 17 Acute Stroke Mortality Rate
    AHRQ Quality Indicators™ (AHRQ QI™) ICD-10-CM/PCS Specification v2021 Inpatient Quality Indicator 17 (IQI 17) Acute Stroke Mortality Rate July 2021 Hospital-Level Indicator Type of Score: Rate Prepared by: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services www.qualityindicators.ahrq.gov DESCRIPTION In-hospital deaths per 1,000 hospital discharges with a principal diagnosis of acute stroke for patients ages 18 years and older. Includes metrics for discharges grouped by type of stroke. Excludes transfers to another hospital, cases admitted from a hospice facility, and obstetric discharges. [NOTE: The software provides the rate per hospital discharge. However, common practice reports the measure as per 1,000 discharges. The user must multiply the rate obtained from the software by 1,000 to report in-hospital deaths per 1,000 hospital discharges.] Stratification of Indicator The indicator is stratified into three groups by the type of stroke: Cases are assigned to strata according to a hierarchy based on risk of mortality, with cases being assigned to the stratum with the highest mortality for which the case qualifies. In the case of Stroke Mortality the current hierarchy is as follows: Strata hierarchy (listed from highest mortality to lowest mortality): 1) Intracerebral hemorrhage 2) Subarachnoid hemorrhage 3) Ischemic stroke Strata are mutually exclusive. If a discharge qualifies for more than one stratum, it will be assigned to the stratum with the highest risk of mortality (Intracerebral hemorrhage, Subarachnoid hemorrhage, Ischemic stroke). July 2021 1 of 7 AHRQ QI™ ICD-10-CM/PCS Specification v2021 IQI 17 Acute Stroke Mortality Rate www.qualityindicators.ahrq.gov NUMERATOR Overall Number of deaths (DISP=20) among cases meeting the inclusion and exclusion rules for the denominator.
    [Show full text]
  • 190.23 - Lipids Testing
    Medicare National Coverage Determinations (NCD) Coding Policy Manual and Change Report (ICD-10-CM) 190.23 - Lipids Testing HCPCS Codes (Alphanumeric, CPT AMA) Code Description 80061 Lipid panel 82465 Cholesterol, serum or whole blood, total 83700 Lipoprotein, blood; electrophoretic separation and quantitation 83701 Lipoprotein blood; high resolution fractionation and quantitation of lipoproteins including lipoprotein subclasses when performed (e.g., electrophoresis, ultracentrifugation) 83704 Lipoprotein, blood; quantitation of lipoprotein particle numbers and lipoprotein particle subclasses 83718 Lipoprotein, direct measurement; high density cholesterol (HDL cholesterol) 83721 Lipoprotein, direct measurement, LDL cholesterol 84478 Triglycerides ICD-10-CM Codes Covered by Medicare Program The ICD-10-CM codes in the table below can be viewed on CMS’ website as part of Downloads: Lab Code List, at http://www.cms.gov/Medicare/Coverage/CoverageGenInfo/LabNCDsICD10.html Code Description B25.2 Cytomegaloviral pancreatitis B52.0 Plasmodium malariae malaria with nephropathy E00.0 Congenital iodine-deficiency syndrome, neurological type E00.1 Congenital iodine-deficiency syndrome, myxedematous type E00.2 Congenital iodine-deficiency syndrome, mixed type E00.9 Congenital iodine-deficiency syndrome, unspecified E01.8 Other iodine-deficiency related thyroid disorders and allied conditions E02 Subclinical iodine-deficiency hypothyroidism E03.0 Congenital hypothyroidism with diffuse goiter E03.1 Congenital hypothyroidism without goiter NCD 190.23 January
    [Show full text]
  • Approved Diagnosis Codes for Botox
    MONTANA HEALTHCARE PROGRAMS NOTICE June 12, 2018 Physician, Hospital Inpatient, Hospital Outpatient, Mid-Level Practitioner Effective Immediately REVISED Approved Diagnosis Codes For Botox July 1, 2016, Montana Healthcare Programs removed prior authorization requirement for Botox. These services will be reimbursed only if the claim (UB-04 or CMS-1500) is submitted with an approved diagnosis. Provider claims that are filed on CMS-1500 claim form must use the diagnosis pointer (box 24E) to indicate the specific diagnosis related to the procedure code. Botox is approved for the following diagnosis codes: ICD-10 Diagnosis Code Description G04.1 Tropical spastic paraplegia G11.4 Hereditary spastic paraplegia G24.1 Genetic torsion dystonia G24.2 Idiopathic nonfamilial dystonia G24.3 Spasmodic torticollis G24.4 Idiopathic orofacial dystonia G24.5 Blepharospasm G24.8 Other dystonia G24.9 Dystonia, unspecified G25.3 Myoclonus G25.89 Other specified extrapyramidal and movement disorders G35 Multiple sclerosis G36.1 Acute and subacute hemorrhagic leukoencephalitis [Hurst] G36.8 Other specified acute disseminated demyelination G37.0 Diffuse sclerosis of central nervous system G37.1 Central demyelination of corpus callosum G37.2 Central pontine myelinolysis G37.4 Subacute necrotizing myelitis of central nervous system G37.5 Concentric sclerosis [Balo] of central nervous system G37.8 Other specified demyelinating diseases of central nervous system G37.9 Demyelinating disease of central nervous system, unspecified G43.011 Migraine without aura, intractable,
    [Show full text]
  • Statistical Analysis Plan
    Cover Page for Statistical Analysis Plan Sponsor name: Novo Nordisk A/S NCT number NCT03061214 Sponsor trial ID: NN9535-4114 Official title of study: SUSTAINTM CHINA - Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin in subjects with type 2 diabetes Document date: 22 August 2019 Semaglutide s.c (Ozempic®) Date: 22 August 2019 Novo Nordisk Trial ID: NN9535-4114 Version: 1.0 CONFIDENTIAL Clinical Trial Report Status: Final Appendix 16.1.9 16.1.9 Documentation of statistical methods List of contents Statistical analysis plan...................................................................................................................... /LQN Statistical documentation................................................................................................................... /LQN Redacted VWDWLVWLFDODQDO\VLVSODQ Includes redaction of personal identifiable information only. Statistical Analysis Plan Date: 28 May 2019 Novo Nordisk Trial ID: NN9535-4114 Version: 1.0 CONFIDENTIAL UTN:U1111-1149-0432 Status: Final EudraCT No.:NA Page: 1 of 30 Statistical Analysis Plan Trial ID: NN9535-4114 Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin in subjects with type 2 diabetes Author Biostatistics Semaglutide s.c. This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant parties.This
    [Show full text]
  • TCD CPT and ICD 10 Codes
    TCD CPT Codes /ICD-10 Codes 2021 CPT Codes / ICD-10 Codes CPT codes covered if selection criteria are met: 93886 Transcranial Doppler study of the intracranial arteries; complete study 93888 limited study 93890 vasoreactivity study 93892 emboli detection without intravenous microbubble injection 93893 emboli detection with intravenous microbubble injection Other CPT codes related to the CPB: 61635 Transcatheter placement of intravascular stent(s), intracranial (eg, atherosclerotic stenosis), including balloon angioplasty, if performed REIMBURSEMENT INFORMATION: A complete transcranial Doppler evaluation includes ultrasound examination of the right and left anterior circulation and the posterior circulation, including the vertebral arteries and basilar artery. A limited transcranial Doppler evaluation includes two or less of the below mentioned areas. Excludes hand-held Dopplers that do not provide a hard copy or vascular flow bidirectional analysis. Includes complete transcranial Doppler (TCD) study. Includes patient care required to perform/supervise studies and interpret results. Includes ultrasound evaluation of right/left anterior circulation territories and posterior circulation territory. DWL USA, Inc. 30320 Rancho Viejo Road, Suite 105 San Juan Capistrano, CA 92675 www.dwl.us TCD CPT Codes /ICD-10 Codes 2021 ICD-10 Diagnosis Codes That Support Medical Necessity: D57.00 – D57.02 Hb-SS disease with crisis D57.1 Sickle-cell disease without crisis D57.20 Sickle-cell/Hb-C disease without crisis D57.211 – D57.219 Sickle-cell/Hb-C disease
    [Show full text]
  • Supplementary Data
    Supplementary Data Table S1. ICD-9-CM codes for CAP. ICD-9-CM Code Description 481 Pneumococcal pneumonia [Streptococcus pneumoniae pneumonia] 4821 Pneumonia due to Pseudomonas 4822 Pneumonia due to Haemophilus influenzae 48230 Pneumonia due to Streptococcus, unspecified 48231 Pneumonia due to Streptococcus, group A 48232 Pneumonia due to Streptococcus, group B 48239 Pneumonia due to other Streptococcus 48240 Pneumonia due to Staphylococcus, unspecified 48241 Methicillin susceptible pneumonia due to Staphylococcus aureus 48242 Methicillin resistant pneumonia due to Staphylococcus aureus 48249 Other Staphylococcus pneumonia 48281 Pneumonia due to anaerobes 48282 Pneumonia due to Escherichia coli 48283 Pneumonia due to other gram-negative bacteria 48284 Pneumonia due to Legionnaires' disease 48289 Pneumonia due to other specified bacteria 4829 Bacterial pneumonia, unspecified 4830 Pneumonia due to Mycoplasma pneumoniae 4831 Pneumonia due to Chlamydia 4838 Pneumonia due to other specified organism 4845 Pneumonia in anthrax 485 Bronchopneumonia, organism unspecified 486 Pneumonia, organism unspecified Abbreviation: ICD-9-CM, International Classification of Diseases, 9th revision, Clinical Modification. Table S2. MedAssets PSI score criteria and adaptations. Formula to Calculate Score Corresponding Conditions with PSI Score Criteria (present = 1; absent = 0) Available ICD-9-CM Code Age Age at index in years + Gender Female *(−10) + Nursing home resident Nursing home resident *10 + Excluded from the analysis Neoplastic disease Neoplastic disease
    [Show full text]
  • Incidence, Morbidity and Mortality of Patients with Achalasia in England: Findings from a Nationwide Hospital Database and 4 Million Population Based Data
    Incidence, morbidity and mortality of patients with achalasia in England: findings from a nationwide hospital database and 4 million population based data Appendix A: International Classification of Disease codes for Achalasia (HES) K22 – Achalasia of cardia Appendix B: Read codes (The Health Improvement Network) Appendix B1: Achalasia codes Clinical code Description J100.00 Achalasia of cardia Appendix B2: Clinical codes used to identify Hypertension, Diabetes and lipid lowering drugs Diabetes Clinical code Description C10..00 Diabetes mellitus C100.00 Diabetes mellitus with no mention of complication C100000 Diabetes mellitus, juvenile type, no mention of complication C100011 Insulin dependent diabetes mellitus C100100 Diabetes mellitus, adult onset, no mention of complication C100111 Maturity onset diabetes C100112 Non-insulin dependent diabetes mellitus C100z00 Diabetes mellitus NOS with no mention of complication C101.00 Diabetes mellitus with ketoacidosis C101000 Diabetes mellitus, juvenile type, with ketoacidosis C101100 Diabetes mellitus, adult onset, with ketoacidosis C101y00 Other specified diabetes mellitus with ketoacidosis C101z00 Diabetes mellitus NOS with ketoacidosis C102.00 Diabetes mellitus with hyperosmolar coma C102000 Diabetes mellitus, juvenile type, with hyperosmolar coma C102100 Diabetes mellitus, adult onset, with hyperosmolar coma C102z00 Diabetes mellitus NOS with hyperosmolar coma C103.00 Diabetes mellitus with ketoacidotic coma C103000 Diabetes mellitus, juvenile type, with ketoacidotic coma C103100 Diabetes
    [Show full text]
  • Comprehensive Anatomy and Physiology for ICD-10-CM and ICD-10-PCS Coding Contents
    2016 Optum Learning: Comprehensive Anatomy and Physiology for ICD-10-CM and ICD-10-PCS Coding Contents Introduction ................................................................................................................1 Welcome to Comprehensive Anatomy and Physiology for ICD-10-CM and ICD-10-PCS Coding .....................................................................1 Summary ....................................................................................................11 Chapter 1. Introduction to the Human Body ........................................................13 Anatomy Overview .....................................................................................13 Figure 1.1: Tissue ...................................................................................14 Figure 1.2: Anatomical Position .............................................................17 Figure 1.3: Body Planes ..........................................................................19 Figure 1.4: Motion .................................................................................20 Summary ....................................................................................................21 Knowledge Assessment Questions ..............................................................22 Chapter 2. ICD-10-CM: Integumentary System ....................................................25 Anatomic Overview ....................................................................................25 Figure 2.1: Skin .....................................................................................25
    [Show full text]
  • 336 Naegeli's
    336 INDEX N Naegeli's Narrowing - continued - disease 287.1 - artery NEC - continued - leukemia, monocytic (M9863/3) 205.1 -- cerebellar 433.8 Naffziger's syndrome 353.0 -- choroidal 433.8 Naga sore (see also Ulcer, skin) 707.9 -- communicative posterior 433.8 Nagele's pelvis 738.6 -- coronary 414.0 - with disproportion 653.0 --- congenital 090.5 -- causing obstructed labor 660.1 --- due to syphilis 093.8 -- fetus or newborn 763.1 -- hypophyseal 433.8 Nail - see also condition -- pontine 433.8 - biting 307.9 -- precerebral NEC 433.9 - patella syndrome 756.8 --- multiple or bilateral 433.3 Nanism, nanosomia (see also Dwarfism) -- vertebral 433.2 259.4 --- with other precerebral artery 433.3 - pituitary 253.3 --- bilateral 433.3 - renis, renalis 588.0 auditory canal (external) 380.5 Nanukayami 100.8 cerebral arteries 437.0 Napkin rash 691.0 cicatricial - see Cicatrix Narcissism 302.8 eustachian tube 381.6 Narcolepsy 347 eyelid 374.4 Narcosis - intervertebral disc or space NEC - see - carbon dioxide (respiratory) 786.0 Degeneration, intervertebral disc - due to drug - joint space, hip 719.8 -- correct substance properly - larynx 478.7 administered 780.0 mesenteric artery (with gangrene) 557.0 -- overdose or wrong substance given or - palate 524.8 taken 977.9 - palpebral fissure 374.4 --- specified drug - see Table of drugs - retinal artery 362.1 and chemicals - ureter 593.3 Narcotism (chronic) (see also Dependence) - urethra (see also Stricture, urethra) 598.9 304.9 Narrowness, abnormal. eyelid 743.6 - acute NEC Nasal- see condition correct
    [Show full text]
  • The 2012 Coding Manual Collection
    The 2012 Coding Manual Collection SaMple pageS ICD-9-CM Manual, Volumes 1, 2 & 3 (Hospital Edition) ICD-9-CM Manual, Volume 1 & 2 (Professional Edition) HCPCS Level II Manual The following 10 sample pages are from HCpro’s 2011 ICD-9-CM Coding Manual, Volumes 1, 2 & 3 SaMple pageS ICD-9-CM Manual, Volumes 1, 2 & 3 (Hospital Edition) 2011 ICD-9-CM Conventions HCPro’s ICD-9-CM manuals include all the symbols and conventions Please note: Certain categories of codes only consider a particular set of found in the government’s official version (see Preface and ICD-9-CM fifth digits to be a CC condition. Official Guidelines for Coding and Reporting). In addition, HCPro’s ICD- • For example: 9-CM manuals include the following icons and color-coded conventions: Category 403.9x. CC 1 ✓4 TH Fourth digit required. In order to accurately assign a diagnosis This means that ICD-9 code 403.90 is not considered a CC condition, but from this category, it requires the assignment of a fourth digit. 403.91 is designated as a CC condition. • For example: Category 465.x requires a fourth digit of a 0, 8, or 9 to be assigned an accurate code. MCC Major Complication and Comorbidity. This diagnosis is considered a major complication and/comorbidity. Assignment of these ✓5 TH Fifth digit required. In order to accurately assign a diagnosis from diagnoses as an additional code may impact DRG assignment. this category, it requires the assignment of a fifth digit. • For example: 585.6 (End stage renal disease) is • For example: Category 642.0x requires a fifth digit of a 0, 1, 2, 3, or designated as an MCC.
    [Show full text]
  • Partial Thromboplastin Time (PTT)
    2020 MEDICARE NATIONAL COVERAGE DETERMINATION (NCD) - 190.16 PROCEDURE CODE: 85730 Partial Thromboplastin Time (PTT) DLS TEST CODES AND NAMES 516 PART. THROM. TIME (PTT) ICD-10 CODE DESCRIPTION A01.00 Typhoid fever, unspecified A01.01 Typhoid meningitis A01.02 Typhoid fever with heart involvement A01.03 Typhoid pneumonia A01.04 Typhoid arthritis A01.05 Typhoid osteomyelitis A01.09 Typhoid fever with other complications A01.1 Paratyphoid fever A A01.2 Paratyphoid fever B A01.3 Paratyphoid fever C A01.4 Paratyphoid fever, unspecified A02.0 Salmonella enteritis A02.1 Salmonella sepsis A02.20 Localized salmonella infection, unspecified A02.21 Salmonella meningitis A02.22 Salmonella pneumonia A02.23 Salmonella arthritis A02.24 Salmonella osteomyelitis A02.25 Salmonella pyelonephritis A02.29 Salmonella with other localized infection A02.8 Other specified salmonella infections A02.9 Salmonella infection, unspecified A41.9 Sepsis, unspecified organism A91 Dengue hemorrhagic fever A92.0 Chikungunya virus disease A95.0 Sylvatic yellow fever A95.1 Urban yellow fever A95.9 Yellow fever, unspecified A96.0 Junin hemorrhagic fever A96.1 Machupo hemorrhagic fever A96.8 Other arenaviral hemorrhagic fevers A96.9 Arenaviral hemorrhagic fever, unspecified A98.0 Crimean-Congo hemorrhagic fever A98.1 Omsk hemorrhagic fever A98.2 Kyasanur Forest disease Source: www.cms.hhs.gov/mcd Prothombin Time Effective date: 10-1-2016, last updated 1-22-2020 Page 1 of 46 2020 MEDICARE NATIONAL COVERAGE DETERMINATION (NCD) - 190.16 PROCEDURE CODE: 85730 Partial Thromboplastin
    [Show full text]
  • 190.17 - Prothrombin Time (PT)
    Medicare National Coverage Determinations (NCD) Coding Policy Manual and Change Report (ICD-10-CM) 190.17 - Prothrombin Time (PT) HCPCS Codes (Alphanumeric, CPT AMA) Code Description 85610 Prothrombin Time ICD-10-CM Codes Covered by Medicare Program The ICD-10-CM codes in the table below can be viewed on CMS’ website as part of Downloads: Lab Code List, at http://www.cms.gov/Medicare/Coverage/CoverageGenInfo/LabNCDsICD10.html Code Description A01.00 Typhoid fever, unspecified A01.01 Typhoid meningitis A01.02 Typhoid fever with heart involvement A01.03 Typhoid pneumonia A01.04 Typhoid arthritis A01.05 Typhoid osteomyelitis A01.09 Typhoid fever with other complications A01.1 Paratyphoid fever A A01.2 Paratyphoid fever B A01.3 Paratyphoid fever C A01.4 Paratyphoid fever, unspecified A02.0 Salmonella enteritis A02.1 Salmonella sepsis A02.20 Localized salmonella infection, unspecified A02.21 Salmonella meningitis A02.22 Salmonella pneumonia A02.23 Salmonella arthritis A02.24 Salmonella osteomyelitis NCD 190.17 January 2021 Changes ICD-10-CM Version – Red Fu Associates, Ltd. January 2021 1 Medicare National Coverage Determinations (NCD) Coding Policy Manual and Change Report (ICD-10-CM) Code Description A02.25 Salmonella pyelonephritis A02.29 Salmonella with other localized infection A02.8 Other specified salmonella infections A02.9 Salmonella infection, unspecified A18.84 Tuberculosis of heart A41.9 Sepsis, unspecified organism A91 Dengue hemorrhagic fever A92.0 Chikungunya virus disease A95.0 Sylvatic yellow fever A95.1 Urban yellow fever
    [Show full text]